Abstract The neuropathology of Alzheimer's disease (AD) is characterized by the accumulation of amyloid peptide Ab in the brain derived from proteolytic cleavage of the amyloid precursor protein (APP). Vaccination of mice with plasmid DNA coding for the human Ab 42 peptide together with low doses of preaggregated peptide induced antibodies with detectable titers after only 2 weeks. One serum was directed against the four aminoterminal amino acids DAEF and differs from previously described ones. Both immune sera and monoclonal antibodies solubilized preformed aggregates of Ab 42 in vitro and recognized amyloid plaques in brain sections of mice transgenic for human APP. Passive immunization of transgenic AD mice caused a significant and rapid reduction in brain amyloid plaques within 24 h. The combined DNA peptide vaccine may prove useful for active immunization with few inoculations and low peptide dose which may prevent the recently described inflammatory reactions in patients. The monoclonal antibodies are applicable for passive immunization studies and may lead to a therapy of AD.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder which is preceded by the deposition of amyloid-b (Ab) peptides into Ab plaques and brain blood vessel walls [1] . The Ab peptides are 39-43 amino acids in length and derived from sequential proteolytic cleavage of the amyloid precursor protein (APP) [2] . APP is a large membrane protein expressed ubiquitously throughout many tissues including brain. Ab peptides convert from soluble molecules to insoluble aggregates in a concentration-dependent manner. These amyloid aggregates are formed from a soluble, mainly coiled, and slightly a-helical form and are characterized by a high degree of b-sheets, a fibrillar morphology in electron microscopy, and the ability to bind and alter spectroscopic properties of thioflavin [3] . Recently evidence has accumulated which suggests that AD is a synaptic failure due to diffusible oligomers of amyloid peptides [4] .
A mouse model of brain amyloid plaque formation expresses the human APP gene with a familial AD mutation (APP V717F) under the control of a neuronal promoter [5] . A mouse model with a transgene expressed in the pancreas has also been described (NORBA mice) [6] . Here an AD mouse model was used overexpressing human APP in the brain of heterozygotic transgenic mice, with mutations K670N, M671L, the Swedish variant (HuAPP 695 SWE) [7] . The transgenic expression of APP in the brain leads to increased concentrations of Ab 42 and to the formation of amyloid plaques during aging with disease symptoms detectable as behavioral changes between 12-18 months of age. At early stages diffuse amyloid deposits can be detected in brain sections by immunohistochemical analysis or by enzyme-linked immunosorbent assay (ELISA) in brain extracts [7] , at later stages plaques become detectable by dyes such as thioflavins or Congo red [3] .
Several studies with APP-transgenic mice have demonstrated that active or passive immunization against the Ab peptide leads to a reduction in amyloid plaque burden and an improvement in memory impairment [8, 9] . Monoclonal antibodies generated previously were directed against the N-terminal 12-16 residues of the peptide and cross-react with the monomeric peptide [10, 11] , possibly due to the fact that amyloid aggregates exhibit an exposed unstructured N-terminal region [12] . Conformational antibodies against the Ab fibrils have also been reported [13] . Another monoclonal antibody, m266, directed against a central region of Ab (amino acids [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] reduced the amyloid burden of the brain in APP-transgenic mice and reversed memory defects [14, 15, 16] . After peripheral injection of m266 plasma levels of Ab peptide increased rapidly, presumably by facilitating the efflux of soluble Ab peptide from the brain. Two other antibodies, AMY-33 and 6F/3D, were raised against Ab peptides 1-28 and 8-17, respectively, and prevented aggregation in vitro [17] . One antibody is known, 3D6, which binds to the amino terminal amino acids and rapidly induced a reduction in amyloid plaque burden in vivo [18] . Here two commercially available antibodies 4G8 [19] and 6H1 were used as controls. They are directed against the amino acid residues 17-24 and 1-17 of human and mouse Ab, respectively.
In a previous study antibodies against Ab plaques were produced by using aggregated Ab 42 peptides in conjunction with Freund's complete adjuvant at a dose of 100 g antigen per injection for a total number of 11 immunizations [20] . Five different peptide immunization procedures have been recently compared [21] . A liposomebased vaccination has also been described, which caused a reduction in Ab plaques in the pancreas of transgenic mice [6] . Peptide immunizations in patients caused inflammation in the brain and led to the halt of a clinical trial [22] .
Vaccination with plasmid DNA encoding tumor-associated antigens or antigens derived from various pathogens leads to the expression and presentation of foreign antigens over a prolonged period of time at low levels, inducing both broad humoral and cellular immune responses (reviewed in [23, 24, 25] ). These antigen-specific immune responses can be further enhanced by boosting with corresponding peptides, proteins or viral vectors expressing the antigens [24, 26] . DNA vaccination induces Th1 or Th2 type immune response depending on the route of injection, amount of DNA, and the nature of the antigen [27] .
In this study we describe an effective vaccination procedure using plasmid DNA coding for Ab 42 in combination with a low dose of the aggregated Ab 42 peptide in the absence of adjuvants. The rationale for this combined vaccination approach is to provide an aggregated Ab 42 peptide nucleus for the plasmid DNA encoded Ab 42 peptide and to boost the primary immune response raised by the ectopically expressed peptide. This immunization leads to a rapid generation of Ab 42 peptide specific antibody titers detectable after dilution of up to 1:1.000 within 2 weeks, which can be increased by further inoculations. One antibody recognized the aminoterminal sequence DAEF and differs from other known antibodies. This mouse was used for preparation of monoclonal antibodies. Using sera and monoclonal antibodies for passive immunization we demonstrate solubilization of preformed aggregates of Ab 42 in vitro, staining of plaques in brain sections, and lysis of plaques in vivo of transgenic APP mice. Thus we describe a novel type of DNA peptide vaccine for active immunization which may be better tolerated when applied to patients than the peptide only vaccine, which recently failed in patients. Furthermore we describe a passive immunization which may lead to new insights on disease mechanism and a therapy of AD.
Material and methods

Plasmids
For the construction of pVR1012tPA-Ab 42 , the coding sequence of Ab 42 was amplified by PCR and cloned into the expression vector pVR1012-tPA [28] using the restriction sites NheI and BamI. The construction of pVR1012-muIL-12 and pVR1012 granulocytemacrophage colony-stimulating factor (GM-CSF) have been described earlier [29] . Large-scale preparation of plasmid DNA was performed as previously described [29] .
Peptides
For immunization, Ab 42 peptide [1] (Bachem, Bubendorf, Switzerland) was dissolved in PBS and aggregated by incubation on a shaker for 48 h at 37C at a concentration of 10 mg/ml. For intramuscular injection, aggregated Ab 42 peptide was suspended in PBS to a concentration of 2 mg/ml.
Cell cultures COS7 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 2 mM glutamic acid, and penicillin/streptomycin. Cells were transfected with pVR1012 control vector or pVR1012tPA-Ab 42 using the calcium phosphate method [30] . At 72 h posttransfection the cells were subjected to immunofluorescence analysis using the monoclonal antibody 6H1 (Evotec Neurosciences, Hamburg, Germany) for detection of human Ab.
Active immunization
For active immunization wild-type mice from SWE breeding were used at 4-6 weeks of age. DNA (200 g in 200 l PBS) was injected intramuscularly into both hind legs. Where indicated, Ab 42 encoding DNA was injected in combination with 100 g DNA encoding either interleukin (IL) 12 or GM-CSF (total volume 200 l PBS). For peptide immunization mice were injected into both hind legs with 20 g Ab 42 peptide in 200 l PBS without adjuvant. All mice were immunized at 4-week intervals for up to 12 immunizations. Blood samples were taken 2 days after every vaccination. For control purposes vaccinations were performed with DNA or peptide only.
Passive immunization
Tg(huAPP 695 .SWE; SwAPP) mice at 16-20 months of age were passively immunized with 200-300 l undiluted sera collected from mice that had been actively immunized as indicated. SwAPP mice were injected four times every 3-4 days, killed 24 h after the last immunization, and analyzed by immunohistochemical staining or ELISA [7] . SwAPP mice receiving sera from mice immunized with DNA peptide combinations were treated once for 1 day or twice at 2-days intervals and killed 1 day later.
Quantification of Ab 42 in brain lysates
For quantification of sodium dodecyl sulfate (SDS) soluble Ab brain tissue was homogenized in lysis buffer containing 2% SDS, 1% Triton X-100, 20 mM Tris (pH 7.6), 137 mM NaCl, and 1 complete proteinase inhibitor mixture (Roche Molecular Biochemicals, Basel, Switzerland) [7] . Cleared lysates were collected following centrifugation at 25,000 g for 30 min at 4C. The concentration of Ab 42 peptide in each sample was determined by ELISA (Innogenics, Switzerland) according to the provider's instructions. Statistical significance of the antibody titers raised against the Ab 42 peptide was determined by Student's t test.
Ab 42 ELISA for serum antibodies Antibodies specific for the Ab 42 peptide were detected and quantified by ELISA using disaggregated Ab 42 peptide as described [31] .
Thioflavin T binding assay
The disaggregation capacity of mouse sera and monoclonal antibodies in vitro was determined by the amount of thioflavin T binding to b-sheets using the thioflavin T-binding assay or ELISA as described [6, 12] . Statistical significance of the solubilization capacity of individual antibody clones was determined by Student's t test.
Generation of Ab 42 -specific monoclonal antibodes
Spleen cells of mouse 697 were fused with myeloma NS-1 cells for generation of monoclonal antibodies as described [32] . Hybridoma cells producing antibodies specific for Ab 42 peptide were identified by Ab 42 ELISA. Five clones were subjected to subcloning and grown to mass cultures. The antibodies were purified by affinity chromatography before immunohistochemical use.
Epitope mapping
For epitope mapping 13mer peptides with two amino acid overlaps spanning the Ab 42 sequence were synthezised using SPOT synthesis and immobilized on filters or glass chips using 0.3-0.6 mol per spot at Jerini AG, Berlin [33] . The peptide supports were incubated with sera at 1:1.000 dilution as described [34] . Peptide bound antibodies were detected using a peroxidase-labeled antimouse IgG polyclonal antibody together with a chemiluminescent substrate and the LumiImager (Roche Diagnostics, Mannheim, Germany).
Immunohistochemistry
Sera from actively immunized wild-type mice were diluted 1:10, 1:100, and 1:1.000 in PBS and used for detection of amyloid plaques in paraffin embedded brain sections of a 12 months old transgenic SwAPP mouse. The monoclonal antibody 4G8 (1:1.000 diluted; Signet Pathology Systems, Dedham, Mass., USA) was used as the positive control. To determine the number of amyloid plaques of passively immunized mice, coronal brain sections (5 m) were immunostained with the antibody 4G8 (dilution 1:1.000) and plaque burden was estimated in five individual sections of each animal.
Results
Cloning and expression of Ab 42
The plasmid comprises the human cDNA coding for the Ab 42 fused to the tissue-type plasminogen activator (tPA) secretory signal under the control of the cytomegalovirus -immediate early enhancer/promoter region and the pVR1012 backbone (Fig. 1a) . Expression of Ab 42 was verified by immunofluorescence staining with the antibody 6H1 in transiently transfected COS7 cells (Fig. 1b) and quantified by ELISA for the expression of human No adjuvant was used. This is in contrast to previous peptide vaccinations, where much higher amounts of peptide were administered combined with Freund's complete adjuvant, phage coupled to bovine serum albumin or liposomes [6, 10, 20] . Antibody titers determined by ELISA showed that the combination of DNA and peptide vaccination described here resulted in detectable antibody titers at a dilution of 1:1.000 after only one immunization (Fig. 2a) . The observed increase in antibody titers specific for Ab 42 was significant 6 (P<0.098), 8 (P<0.02) and 10 weeks (P<0.00001) after the initial injection compared to the control vaccination with empty backbone DNA (Fig. 2a) . The DNA peptide vaccination induced higher titers up to 1:10.000 after four to eight injections (P<0.016 and P<0.088, respectively, compared to vaccination with empty vector DNA), which further increased with more immunizations (Fig. 2b) . Combination of Ab 42 -encoding DNA with DNA encoding IL-12 (data not shown) or GM-CSF without peptide induced very low antibody titers (Fig. 2b) . Control experiments showed that the peptide alone gave a weak and transient response. Empty backbone DNA control and DNA encoding Ab 42 alone were both negative. The combination of backbone DNA and peptide, however, gave rise to significant Ab 42 -specific antibody titers, 8 and 10 weeks after the first vaccination (P<0.0279, and P<0.0043, respectively). This may be attributable to CpG sequences in the DNA backbone (Fig. 2a , open circles) [35] .
In vitro lysis of aggregates by thioflavin binding assay
To determine the ability of antibodies to dissolve Ab peptide aggregates in vitro we aggregated Ab 42 by incubation at 37C for 7 days without agitation [3] . This aggregate binds the fluorescent dye thioflavin T and allows determination of the degree of solubilization, measured either by ELISA of released solubilized Ab peptides or as a shift of absorbance and emission from 380 and 430 nm to 450 and 480 nm of thioflavin bound to Ab aggregates, respectively. Figure 3a shows one of three independent experiments in which mouse sera were tested by ELISA whereby mouse 697 exhibited the strongest disaggregation capacity in vitro. It was vaccinated with a combination of Ab-encoding DNA and peptide. Monoclonal antibodies were generated from this mouse, concentrated 50-fold from hybridoma supernatants and tested for their disaggregation capacity using the thioflavin binding assay (Fig. 3b) . The clones 16E6H9 (P<0.0024), 14E6C9, (P<0.015), and 16G1F12, (P<0.015) showing significant solubilization of aggregated Ab 42 were selected for further subcloning.
Epitope mapping of antisera
The sera obtained were analyzed for their ability to bind to linear peptides derived from Ab 42 . Sixteen consecutive peptides 13 amino acids in length with two amino acids overlaps were spotted onto filter paper. Binding was quantified by chemiluminescence (Fig. 4) [33] . Serum Fig. 1 Reactivity of sera with amyloid plaques Frontal brain sections from a 12 months old mouse transgenic for human APP (tgHuAPP 695 SWE) [5] were incubated with antisera at dilutions from 1:10 to 1:1.000 obtained from actively immunized mice and were compared to a commercially available control antibody 4G8.
Six sera were tested using five slices for each (Fig. 5a) . The results show that the serum of mouse 697, which was immunized with the Ab-encoding DNA and peptide combination, stained the plaques at a dilution of 1:100 (Fig. 5a, C ). Mice immunized with DNA encoding Ab 42 and DNA encoding GM-CSF (mouse 707) or IL-12 (mouse 709) showed staining of neurons only (Fig. 5a, F) or no staining at all (Fig. 5a, G) , respectively. Sera of all other mice were negative for staining. Antiserum from mouse 3583, which was immunized by peptide and control vector, gave rise to staining of plaques (Fig. 5a, H) . Two monoclonal antibodies derived from mouse 697, 16G1, and 16E6, harvested from hybridoma supernatants, both containing 42.5 mg/ml, allowed staining of plaques at a dilution of 1:1000, whereby 16E6 was specific for plaques and 16G1 also recognized APP (Fig. 5a, I , K).
Plaque reduction in vivo by passive immunization
For passive immunization transgenic mice at the age of 16-20 months received antisera from mice vaccinated with the Ab-DNA peptide combination, DNA encoding Ab 42 alone, DNA encoding Ab 42 combined with DNA encoding IL-12, GM-CSF, or only empty backbone as control DNA. A quantity of 250-300 l of the sera was injected into the tail veins. Serum of mouse 697, vaccinated with the Ab-DNA peptide combination, was injected once (300 l) in one mouse, which was killed 1 day later. Another mouse was injected twice within 3 days and killed 1 day later. Six brain sections of each immunized mouse were taken throughout the cortex and hippocampus and stained with the control mAb 4G8. The number of plaques was evaluated by microscopy and compared to those of untreated mice. As can be seen in Fig. 5b , the amyloid plaque burden was low 24 h after a single injection (Fig. 5b, C) . With two injections within 4 days no plaques were detected (Fig. 5b, D) . Sera from the other mice showed no reduction in plaques (Fig. 5b, E-H) .
As an alternative for analyzing brain sections of aged transgenic mice younger mice at about 5 months of age were passively vaccinated and the levels of Ab 42 in SDS extracts of brains were determined by ELISA [7] . Passive immunization with two of the monoclonal antibodies (clones 16E6 lanes 5-8 and 16G1 lanes 9-13) showed a significant reduction in brain levels of Ab 42 (Fig. 5c) . Lanes 1-4 show untreated control (lanes 3 and 5 failed) .
In addition to the evaluation of plaque reduction in the brains of human APP transgenic (tgHuAPP 695 SWE) mice by passive immunization, we also wished to test the combined DNA vaccine Ab 42 peptide active immunization protocol. However, the overexpression of the human APP protein in transgenic (HuAPP 695 .SWE) mice leads to an increased spontaneous mortality in an age-dependent manner. Under standard laboratory conditions only approx. 50% of the animals reach an age of 1 year. Unfortunately, too many of the heterocygotic APP transgenic mice died during the study to allow a meaningful interpretation of the results. However, the observed mortality rate of mice actively immunized with DNA, peptide, or a combination of the two was not increased when compared to untreated control animals (data not shown).
Discussion
Vaccination against the amyloid Ab protein is of high interest. Here we describe a vaccination procedure using plasmid DNA combined with peptides. A few injections were sufficient to raise relevant antibody titers in all eight mice. The titers increased with the number of inoculations. DNA as a vaccine has been applied in many preclinical as well as clinical settings and proved to be extremely safe but of rather low efficiency [36] . The combination of DNA with peptide boosts increased the efficiency, by which both the humoral and the cellular immune response were involved. DNA prime peptide boost regimens are about to enter clinical trials as vaccines against various pathogens such as human immunodeficiency virus and Ebola virus. A long-term follow-up study in patients has not shown any signs of anti-DNA antibodies as a risk for autoimmune diseases and was well tolerated without any side effects [37] .
Peptide vaccines have been tested previously in combination with Freund's adjuvant, liposomes, phages and by different routes [6, 10, 20, 21] . In most previous tests 50-100 g of peptide per injection was used. Recently patients with progressed AD were treated with amyloid Ab peptide vaccines in a clinical trial. It resulted in the occurrence of meningoencephalitis in some of the patients and led to a halt of the clinical trial [22, 31] . The DNA construct combined with the aggregated Ab peptide used here induced antibodies that specifically recognized the very aminoterminal four amino acids DAEF of the amyloid Ab peptide. The serum when injected intravenously for passive immunization of SwAPP transgenic mice 16-20 months old induced a rapid reduction in plaques within 24 h after treatment.
Passive immunizations have been described in transgenic mice with m266 (recognizing N-terminal sequences) [14, 15, 16] and monoclonal antibodies 3D6 and 10D5 (recognizing N-terminal sequences) [18] . They bind to Ab plaques and some lead to reduction of plaque burden (for review see [38] ). m266 reversed memory defects in learning and recognition tasks [16] . The monoclonal antibodies described here were derived from the mouse 697, which produced serum against DAEF, and differ from sera previously described. Reduction in the amount of Ab in the brains of young (5 months of age) and amyloid plaques of old (16-20 months of age) AD mice was observed here. The reduction was very rapid and occurred within 24 h after a single injection of 200-300 l undiluted sera. A rapid biological response has previously been reported and was attributed to Fc-medi- Fig. 4 Peptide scanning. Sixteen consecutive peptides, 13 amino acids in length, which overlapped by 11 amino acids with both neighboring peptides, were synthesized, spotted onto membranes, and analyzed with the sera indicated for recognition of epitopes. Mouse 697, which recognized the aminoterminal sequence DAEF, was used for preparation of monoclonal antibodies [18] . The alternative theory of a "peripheral sink" has also been proposed, whereby the formation of antigen-antibody complexes in the periphery sequesters Ab peptides and prevents the deposition of new plaques. Alternatively, plaques may be physically disrupted by the antibody. The short time period required for disruption of plaques may be due to physical or conformational changes in the plaques induced by the antibody. A monoclonal antibody of this kind has been described for the scrapie prion PrP sc by Prusiner and colleages [39] . However, passive immunization has recently been performed in APP23 transgenic mice with 20 weekly injections of 500 g monoclonal antibody that recognizes amino acids 3-6. After 5 months the mice developed cerebral hemorrhages, presumably due to the weakening of amyloidotic vessel walls by local inflammatory reactions [40] .
The effect of empty DNA plasmid controls combined with the Ab peptide was unexpected since the antibody titer and specificity resembles that with Ab DNA. It may be possible to use only CpG oligonucleotides with the Ab peptide for clinical use.
In summary, we present two new aspects, a new active immunization procedure with a Ab-DNA peptide combination and a new monoclonal antibody for passive immunization. The combined DNA peptide vaccine differs significantly from all previous ones since no adjuvant was used and the amount of peptide used, 20 g, per injection was very low. This is important in view of the suspicion that the use of adjuvants may support a Th1-mediated immune response, which has been implicated in autoimmune diseases and may have contributed to the adverse response in some patients vaccinated with the Ab 42 peptide. Moreover, analysis of the Ig subtype of the Ab 42 peptide-specific monoclonal antibodies, revealed that all of them were of the IgG1 subtype. This finding indicates that the combined DNA vaccine/Ab 42 peptide vaccination approach induces a Th2 type of response, which may be an important advantage by inhibiting an autoimmune reaction in patients. A few injections of the DNA peptide combination gave rise to significant antibody titers which could be increased by additional boosts. Furthermore, a monoclonal antibody may be useful for characterization of molecular mechanisms underlying the rapid solubilization of plaques in vivo and in vitro and may be developed into a therapeutic vaccine applied at early stages of AD to prevent disease progression.
